相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
Katriina J. Peltola et al.
EUROPEAN UROLOGY FOCUS (2020)
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
Riikka Oksala et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
Evan Y. Yu et al.
INVESTIGATIONAL NEW DRUGS (2018)
Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer
Athanasios E. Dellis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of non-metastatic castrate-resistant prostate cancer: A systematic review
Yohann Loriot et al.
CANCER TREATMENT REVIEWS (2018)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
Karim Fizazi et al.
CLINICAL GENITOURINARY CANCER (2018)
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami et al.
COMMUNICATIONS BIOLOGY (2018)
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Howard I. Scher et al.
EUROPEAN UROLOGY (2017)
Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
Tomasz M. Beer et al.
EUROPEAN UROLOGY (2017)
Darolutamide (ODM-201) for the treatment of prostate cancer
Neal D. Shore
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
D. E. Rathkopf et al.
ANNALS OF ONCOLOGY (2017)
Androgen receptor aberrations in the era of abiraterone and enzalutamide
Florian Jentzmik et al.
WORLD JOURNAL OF UROLOGY (2016)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K. N. Chi et al.
ANNALS OF ONCOLOGY (2016)
Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence
Isabel Coutinho et al.
ENDOCRINE-RELATED CANCER (2016)
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer
Athanasios Dellis et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
David F. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Neal D. Shore et al.
LANCET ONCOLOGY (2016)
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
Emmanuel S. Antonarakis et al.
ONCOLOGIST (2016)
Utility of novel androgen receptor therapies in the real world: A nuanced approach
Mallika Dhawan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide
Richard M. Bambury et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
C. Parker et al.
ANNALS OF ONCOLOGY (2015)
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Gerhardt Attard et al.
CLINICAL CANCER RESEARCH (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Androgen Receptor Targeting Drugs in Castration-Resistant Prostate Cancer and Mechanisms of Resistance
D. J. Crona et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Observational studies and the natural history of screen-detected prostate cancer
Peter C. Albertsen
CURRENT OPINION IN UROLOGY (2015)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies
A. Omlin et al.
INVESTIGATIONAL NEW DRUGS (2015)
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
Vincent C. O. Njar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Castration-Resistant Prostate Cancer: AUA Guideline Amendment
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2015)
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations
Daan Joost De Maeseneer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
Aaron Balog et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor
Youzhi Tong et al.
CANCER RESEARCH (2014)
Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
Ziyang Yu et al.
CLINICAL CANCER RESEARCH (2014)
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
Srikala S. Sridhar et al.
EUROPEAN UROLOGY (2014)
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
R. Ferraldeschi et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
D. Bianchini et al.
BRITISH JOURNAL OF CANCER (2013)
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
Dana Rathkopf et al.
CANCER JOURNAL (2013)
Progress in emerging therapies for advanced prostate cancer
Stephane Oudard
CANCER TREATMENT REVIEWS (2013)
Abiraterone acetate for the treatment of prostate cancer
Charles J. Ryan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents-as an Approach to Treatment of Advanced Prostate Cancer
Puranik Purushottamachar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Sarah A. Loddick et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Overcoming mutation-based resistance to antiandrogens with rational drug design
Minna D. Balbas et al.
ELIFE (2013)
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Vincenzo Pagliarulo et al.
EUROPEAN UROLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
Dana Rathkopf et al.
CLINICAL CANCER RESEARCH (2011)
Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
Punit Saraon et al.
CLINICAL CHEMISTRY (2011)
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
Yixian Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Molecular genetics of prostate cancer: new prospects for old challenges
Michael M. Shen et al.
GENES & DEVELOPMENT (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values
Vivek K. Wadhwa et al.
BJU INTERNATIONAL (2009)
Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
Mara P. Steinkamp et al.
CANCER RESEARCH (2009)
A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
Zhiyong Guo et al.
CANCER RESEARCH (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity
Arnina Zoubeidi et al.
CANCER RESEARCH (2007)
Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells
Masayuki Kamada et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis
HI Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
VD Handratta et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Metastatic prostate cancer treated by flutamide versus cyproterone acetate -: Final analysis of the European organization for research and treatment of cancer (EORTC) protocol 30892
FH Schröder et al.
EUROPEAN UROLOGY (2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
